Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. (TVTX) director Jeffrey A. Meckler reported option exercises and related share sales on September 10, 2026. He exercised stock options for 10,000 shares at $17.44 and 10,000 shares at $26.52, receiving a total of 20,000 shares of common stock.
On the same date, he sold 20,000 shares of common stock in market transactions, split into four tranches of 1,700; 1,200; 14,000; and 3,100 shares at weighted average prices of $65.3917, $66.15, $67.4634, and $68.088, respectively. These sales were made under a Rule 10b5-1(c) trading plan adopted on June 11, 2026, and involved shares underlying fully vested options expiring in 2027 and 2028.
Travere Therapeutics, Inc. (TVTX) has a notice under Rule 144 indicating that director Jeffrey Meckler plans to sell up to 20,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC after a cash exercise of stock options on September 10, 2026.
The filing lists an aggregate market value of $1,324,400 for the 20,000 shares, with sales expected to occur on or after September 10, 2026 on the NASDAQ market.
Travere Therapeutics, Inc. (TVTX) reported that its Chief Financial Officer, Christopher R. Cline, sold 642 shares of common stock on September 2, 2026 at $66.37 per share. According to the company’s disclosure, this sale was a mandatory “sell to cover” transaction to satisfy tax withholding on vested restricted stock units and was not a discretionary trade by the officer, and no Rule 10b5-1 trading plan is reported.
Travere Therapeutics, Inc. (TVTX) director Gary A. Lyons reported an exercise-and-sell sequence over August 17–18, 2026. He exercised stock options for 10,000 shares of common stock at an exercise price of $17.44 per share (options fully vested and expiring May 17, 2027), acquiring 10,000 shares. He then sold 10,000 shares of common stock in multiple tranches at weighted-average prices ranging from about $62.53 to $64.16 per share. All sales were made pursuant to a written trading plan adopted on May 18, 2026 under Rule 10b5-1(c).
Travere Therapeutics, Inc. (TVTX) received a notice that director Gary Lyons plans to sell company common stock under Rule 144. The planned transaction involves 5,000 shares of common stock, with a stated aggregate market value of $317,650.00, through Morgan Stanley Smith Barney on or about 08/18/2026. The shares are to be sold in connection with the exercise of stock options for cash. The notice also lists a prior 10b5-1 sale of 5,000 shares on 08/17/2026 for total proceeds of $315,985.50.
Travere Therapeutics, Inc. is the subject of an amended Schedule 13G filing by Armistice Capital, LLC and Steven Boyd. The reporting persons disclose beneficial ownership of 1,572,539 shares of Travere common stock, representing 1.67% of the class, with shared voting and dispositive power over all reported shares and no sole voting or dispositive power.
Bank of America Corporation, through certain wholly owned subsidiaries, reported beneficial ownership of 5,439,155 shares of Travere Therapeutics, Inc. common stock on a Schedule 13G. This represented 5.8% of the class, based on 94,174,767 shares outstanding as of June 30, 2026, as reported by Travere in a Form 10-Q filed August 4, 2026.
Bank of America reported no sole voting or dispositive power over Travere shares. It reported shared voting power over 5,103,492 shares and shared dispositive power over 5,325,237 shares, reflecting positions held across subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co of Delaware.
State Street Corporation reported its beneficial ownership of Travere Therapeutics, Inc. common stock. State Street, through its investment management subsidiaries, reported beneficially owning 4,256,224 shares of common stock, representing 4.6% of the class as of June 30, 2026.
The shares are held with no sole voting or dispositive power; State Street reported shared voting power over 4,010,969 shares and shared dispositive power over 4,256,224 shares. The filing indicates ownership of 5 percent or less of the class and identifies several State Street Global Advisors entities as the investment adviser subsidiaries through which the holdings are maintained.
FMR LLC and Abigail P. Johnson report beneficial ownership of TRAVERE THERAPEUTICS INC common stock on an amended Schedule 13G.
FMR LLC reports beneficial ownership of 7,142,482.22 shares of common stock, representing 7.7% of the class, with 6,173,667.45 shares having sole voting power and all 7,142,482.22 shares subject to sole dispositive power. Abigail P. Johnson reports sole dispositive power over the same 7,142,482.22 shares, with no voting power. The filing states that one or more other persons have rights to dividends or sale proceeds in these shares, but no such person has an interest exceeding five percent of the outstanding common stock.